Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Cancer Health Center

Font Size

Evista May Help Prevent Endometrial Cancer

Osteoporosis Drug May also Prevent Breast Cancer
WebMD Health News

May 16, 2005 (Orlando, Fla.) -- Researchers say a drug prescribed for osteoporosis may protect against endometrial cancer.

Women who took Evista "had about half the risk of endometrial cancer than those not using the drug," says researcher Angela DeMichele, MD, associate professor of medicine at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia.

Evista is a drug known as a selective estrogen receptor modulator (SERM). It has positive estrogen-like effects on bone and protects against osteoporosis -- a bone-thinning disease.

However, the drug also blocks estrogen's effect on breast tissue. Some breast cancer cells grow in response to estrogen. SERMs reduce the risk of breast cancer by blocking estrogen receptors in breast cells.

DeMichele's study shows that Evista may be of benefit for endometrial-cancer protection in addition to its breast cancer protective effects. Endometrial cancer is a cancer of the lining of the uterus.

Evista Drops Risk of Cancer

For high-risk women, tamoxifen is the first and only drug approved for the prevention of breast cancer. But tamoxifen has been associated with an increased risk of endometrial cancer.

So doctors have been searching for alternative drugs for breast cancer prevention, including the bone-building drug Evista. The new study shows that Evista protects against endometrial cancer.

In DeMichele's study, women who used Evista were 50% less likely to have been diagnosed with endometrial cancer than women who never used the drug.

Overall, "users of tamoxifen were about three times more likely to develop endometrial cancer than users of Evista," DeMichele says. And women who took tamoxifen were about 50% more likely to develop the disease than nonusers, she says.

The study was presented at the annual meeting of the American Society for Clinical Oncology.

Ongoing Trial Could Open New Doors for Evista

The study included 547 women with endometrial cancer and 1,412 women without the disease. The researchers were actually looking at genetic risk factors associated with endometrial cancer when they stumbled across the link to the drugs.

Despite the promising data, DeMichele stresses that Evista is approved only for the prevention and treatment of osteoporosis.

Today on WebMD

Colorectal cancer cells
New! I AM Not Cancer Facebook Group
Lung cancer xray
See it in pictures, plus read the facts.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Real Cancer Perspectives
Jennifer Goodman Linn self-portrait
what is your cancer risk
colorectal cancer treatment advances
breast cancer overview slideshow
prostate cancer overview
lung cancer overview slideshow
ovarian cancer overview slideshow
Actor Michael Douglas